R2CHOP and DLBCL
This phase II study examined the efficacy of lenalidomide in combination with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R2CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Patients (n = 64) with stage II-IV CD20+ DLBCL were enrolled in the study with 60 patients being evaluable for response. The molecular subtype of DLBCL was determined by tumour immunohistochemistry and classified as either germinal centre B-cell (GCB) or non-GCB in those receiving R2CHOP and 87 control patients with DLBCL from the Lymphoma Database who received R-CHOP only. The overall response rate was 98% (59 of 60) with 80% (48 of 60) achieving a complete response. At 24 months, event-free survival and overall survival (OS) rates were 59% (95% CI, 48% to 74%) and 78% (95% CI, 68% to 90%), respectively. In those receiving R-CHOP, 24-month progression-free survival and OS were 28% versus 64% (p<0.001) and 46% versus 78% (p<0.001) in non-GCB DLBCL versus GCB DLBCL, respectively. For more information, click here.